Abstract
Summary
LPI (LP Information)' newest research report, the “Super Generic Drugs Industry Forecast” looks at past sales and reviews total world Super Generic Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Super Generic Drugs sales for 2023 through 2029. With Super Generic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Super Generic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Super Generic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Super Generic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Super Generic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Super Generic Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Super Generic Drugs.
The global Super Generic Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Super Generic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Super Generic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Super Generic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Super Generic Drugs players cover Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Super Generic Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Traditional Generic Drugs
Biosimilars
Segmentation by application
CNS
Cardiovascular
Genitourinary/Hormonal Drugs
Respiratory
Rheumatology
Diabetes
Oncology
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Super Generic Drugs market?
What factors are driving Super Generic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Super Generic Drugs market opportunities vary by end market size?
How does Super Generic Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
This Insight Report provides a comprehensive analysis of the global Super Generic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Super Generic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Super Generic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Super Generic Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Super Generic Drugs.
The global Super Generic Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Super Generic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Super Generic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Super Generic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Super Generic Drugs players cover Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Super Generic Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Traditional Generic Drugs
Biosimilars
Segmentation by application
CNS
Cardiovascular
Genitourinary/Hormonal Drugs
Respiratory
Rheumatology
Diabetes
Oncology
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Super Generic Drugs market?
What factors are driving Super Generic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Super Generic Drugs market opportunities vary by end market size?
How does Super Generic Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Super Generic Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Super Generic Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Super Generic Drugs by Country/Region, 2018, 2022 & 2029
2.2 Super Generic Drugs Segment by Type
2.2.1 Traditional Generic Drugs
2.2.2 Biosimilars
2.3 Super Generic Drugs Sales by Type
2.3.1 Global Super Generic Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Super Generic Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Super Generic Drugs Sale Price by Type (2018-2023)
2.4 Super Generic Drugs Segment by Application
2.4.1 CNS
2.4.2 Cardiovascular
2.4.3 Genitourinary/Hormonal Drugs
2.4.4 Respiratory
2.4.5 Rheumatology
2.4.6 Diabetes
2.4.7 Oncology
2.4.8 Others
2.5 Super Generic Drugs Sales by Application
2.5.1 Global Super Generic Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Super Generic Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Super Generic Drugs Sale Price by Application (2018-2023)
3 Global Super Generic Drugs by Company
3.1 Global Super Generic Drugs Breakdown Data by Company
3.1.1 Global Super Generic Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Super Generic Drugs Sales Market Share by Company (2018-2023)
3.2 Global Super Generic Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Super Generic Drugs Revenue by Company (2018-2023)
3.2.2 Global Super Generic Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Super Generic Drugs Sale Price by Company
3.4 Key Manufacturers Super Generic Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Super Generic Drugs Product Location Distribution
3.4.2 Players Super Generic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Super Generic Drugs by Geographic Region
4.1 World Historic Super Generic Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Super Generic Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Super Generic Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Super Generic Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Super Generic Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Super Generic Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Super Generic Drugs Sales Growth
4.4 APAC Super Generic Drugs Sales Growth
4.5 Europe Super Generic Drugs Sales Growth
4.6 Middle East & Africa Super Generic Drugs Sales Growth
5 Americas
5.1 Americas Super Generic Drugs Sales by Country
5.1.1 Americas Super Generic Drugs Sales by Country (2018-2023)
5.1.2 Americas Super Generic Drugs Revenue by Country (2018-2023)
5.2 Americas Super Generic Drugs Sales by Type
5.3 Americas Super Generic Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Super Generic Drugs Sales by Region
6.1.1 APAC Super Generic Drugs Sales by Region (2018-2023)
6.1.2 APAC Super Generic Drugs Revenue by Region (2018-2023)
6.2 APAC Super Generic Drugs Sales by Type
6.3 APAC Super Generic Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Super Generic Drugs by Country
7.1.1 Europe Super Generic Drugs Sales by Country (2018-2023)
7.1.2 Europe Super Generic Drugs Revenue by Country (2018-2023)
7.2 Europe Super Generic Drugs Sales by Type
7.3 Europe Super Generic Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Super Generic Drugs by Country
8.1.1 Middle East & Africa Super Generic Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Super Generic Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Super Generic Drugs Sales by Type
8.3 Middle East & Africa Super Generic Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Super Generic Drugs
10.3 Manufacturing Process Analysis of Super Generic Drugs
10.4 Industry Chain Structure of Super Generic Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Super Generic Drugs Distributors
11.3 Super Generic Drugs Customer
12 World Forecast Review for Super Generic Drugs by Geographic Region
12.1 Global Super Generic Drugs Market Size Forecast by Region
12.1.1 Global Super Generic Drugs Forecast by Region (2024-2029)
12.1.2 Global Super Generic Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Super Generic Drugs Forecast by Type
12.7 Global Super Generic Drugs Forecast by Application
13 Key Players Analysis
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Super Generic Drugs Product Portfolios and Specifications
13.1.3 Teva Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Novartis - Sandoz
13.2.1 Novartis - Sandoz Company Information
13.2.2 Novartis - Sandoz Super Generic Drugs Product Portfolios and Specifications
13.2.3 Novartis - Sandoz Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis - Sandoz Main Business Overview
13.2.5 Novartis - Sandoz Latest Developments
13.3 Mylan
13.3.1 Mylan Company Information
13.3.2 Mylan Super Generic Drugs Product Portfolios and Specifications
13.3.3 Mylan Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mylan Main Business Overview
13.3.5 Mylan Latest Developments
13.4 Sun Pharmaceutical
13.4.1 Sun Pharmaceutical Company Information
13.4.2 Sun Pharmaceutical Super Generic Drugs Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Sun Pharmaceutical Main Business Overview
13.4.5 Sun Pharmaceutical Latest Developments
13.5 Aspen
13.5.1 Aspen Company Information
13.5.2 Aspen Super Generic Drugs Product Portfolios and Specifications
13.5.3 Aspen Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Aspen Main Business Overview
13.5.5 Aspen Latest Developments
13.6 Fresenius Kabi
13.6.1 Fresenius Kabi Company Information
13.6.2 Fresenius Kabi Super Generic Drugs Product Portfolios and Specifications
13.6.3 Fresenius Kabi Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Fresenius Kabi Main Business Overview
13.6.5 Fresenius Kabi Latest Developments
13.7 Pfizer (Hospira)
13.7.1 Pfizer (Hospira) Company Information
13.7.2 Pfizer (Hospira) Super Generic Drugs Product Portfolios and Specifications
13.7.3 Pfizer (Hospira) Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer (Hospira) Main Business Overview
13.7.5 Pfizer (Hospira) Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Super Generic Drugs Product Portfolios and Specifications
13.8.3 Sanofi Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Aurobindo
13.9.1 Aurobindo Company Information
13.9.2 Aurobindo Super Generic Drugs Product Portfolios and Specifications
13.9.3 Aurobindo Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Aurobindo Main Business Overview
13.9.5 Aurobindo Latest Developments
13.10 Lupin
13.10.1 Lupin Company Information
13.10.2 Lupin Super Generic Drugs Product Portfolios and Specifications
13.10.3 Lupin Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Lupin Main Business Overview
13.10.5 Lupin Latest Developments
13.11 Dr. Reddy's
13.11.1 Dr. Reddy's Company Information
13.11.2 Dr. Reddy's Super Generic Drugs Product Portfolios and Specifications
13.11.3 Dr. Reddy's Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Dr. Reddy's Main Business Overview
13.11.5 Dr. Reddy's Latest Developments
13.12 Apotex
13.12.1 Apotex Company Information
13.12.2 Apotex Super Generic Drugs Product Portfolios and Specifications
13.12.3 Apotex Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Apotex Main Business Overview
13.12.5 Apotex Latest Developments
13.13 Cipla
13.13.1 Cipla Company Information
13.13.2 Cipla Super Generic Drugs Product Portfolios and Specifications
13.13.3 Cipla Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Cipla Main Business Overview
13.13.5 Cipla Latest Developments
13.14 ENDO (Par Pharmaceutical)
13.14.1 ENDO (Par Pharmaceutical) Company Information
13.14.2 ENDO (Par Pharmaceutical) Super Generic Drugs Product Portfolios and Specifications
13.14.3 ENDO (Par Pharmaceutical) Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 ENDO (Par Pharmaceutical) Main Business Overview
13.14.5 ENDO (Par Pharmaceutical) Latest Developments
13.15 Stada Arzneimittel
13.15.1 Stada Arzneimittel Company Information
13.15.2 Stada Arzneimittel Super Generic Drugs Product Portfolios and Specifications
13.15.3 Stada Arzneimittel Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Stada Arzneimittel Main Business Overview
13.15.5 Stada Arzneimittel Latest Developments
13.16 Krka Group
13.16.1 Krka Group Company Information
13.16.2 Krka Group Super Generic Drugs Product Portfolios and Specifications
13.16.3 Krka Group Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Krka Group Main Business Overview
13.16.5 Krka Group Latest Developments
13.17 Nichi-Iko Pharmaceutical
13.17.1 Nichi-Iko Pharmaceutical Company Information
13.17.2 Nichi-Iko Pharmaceutical Super Generic Drugs Product Portfolios and Specifications
13.17.3 Nichi-Iko Pharmaceutical Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Nichi-Iko Pharmaceutical Main Business Overview
13.17.5 Nichi-Iko Pharmaceutical Latest Developments
13.18 Valeant
13.18.1 Valeant Company Information
13.18.2 Valeant Super Generic Drugs Product Portfolios and Specifications
13.18.3 Valeant Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Valeant Main Business Overview
13.18.5 Valeant Latest Developments
13.19 Zydus Cadila
13.19.1 Zydus Cadila Company Information
13.19.2 Zydus Cadila Super Generic Drugs Product Portfolios and Specifications
13.19.3 Zydus Cadila Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Zydus Cadila Main Business Overview
13.19.5 Zydus Cadila Latest Developments
13.20 Hikma
13.20.1 Hikma Company Information
13.20.2 Hikma Super Generic Drugs Product Portfolios and Specifications
13.20.3 Hikma Super Generic Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Hikma Main Business Overview
13.20.5 Hikma Latest Developments
14 Research Findings and Conclusion